Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193869 | 0.84 | KMT2A (0.50) | L3MBTL1MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7188592 | 0.83 | ALDH1A1 (0.45) | MAPTSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL1466237 | 0.81 | MEN1 (0.43) | L3MBTL1SMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL7195380 | 0.81 | NR1H2 (0.46) | MAPTALDH1A1TSHRTDP1MEN1 | |
| SCHEMBL2271692 | 0.81 | HDAC1 (0.57) | L3MBTL1MAPTNPSR1SMN1; SMN2HTT | |
| SCHEMBL6762455 | 0.81 | HPGD (0.51) | L3MBTL1MAPTNPSR1SMN1; SMN2HTT | |
| SCHEMBL5320711 | 0.81 | ALDH1A1 (0.54) | POLBALDH1A1MEN1KMT2ACYP2C9 | |
| SCHEMBL8687784 | 0.81 | HTR1A (0.46) | MAPTALDH1A1TSHRTDP1MEN1 | |
| SCHEMBL11121836 | 0.80 | CYP1A2 (0.53) | L3MBTL1MAPTNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30548756 | 0.80 | CYP1A2 (0.53) | L3MBTL1MAPTNPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192125-A | Preparation method of oxygen/thioxanthene compound | 湖南科技大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192126-A | Preparation method of oxygen/thioxanthone compound | 湖南科技大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-104710345-B | For preparing 4(2‑(4 aminomethyl phenyl sulfenyls))Compound, its preparation method and the application of Phenylpiperidine | 江苏恩华药业股份有限公司 | 2017-09-05 | — | — | CN | disclosed |
| WO-2016019588-A1 | OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE | THE BROAD INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | L3MBTL1 2206/4885MAPT 4703/4885NPSR1 1830/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | L3MBTL1 2206/4885MAPT 4703/4885NPSR1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.